Lantheus Medical (North Billerica, Massachusetts) reported that it has released phase 1 data for its heart failure PET imaging agent, LMI 1195, which is in development for the evaluation of patients at risk of heart failure or sudden cardiac death. (Medical Device Daily) Read More
